Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass
NCT01373216 on ClinicalTrials.gov · last registry update 2016-02-02
A small phase 3 — 38 participants, against a typical 424. The sponsor logged completion for May 2014. Primary outcome, as filed: Cardiac function - echocardiographic parameters. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Charles University, Czech Republic
- Sponsor type
- Other
- Enrollment
- 38
- Started
- 2011-06
- Primary completion
- 2014-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Cardiac function - echocardiographic parameters
Conditions studied
Coronary Artery Disease · Decreased Left Ventricular Function
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.